Abstract:Zongchao Li, 1 Aonan Dai, 1 Ming Yang, 1 Siyu Chen, 2, 3 Zhenhan Deng, 2, 3, &ast Liangjun Li 1, &ast 1 Department of Orthopaedics, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, People's Republic of China; 2 Department of Sports Medicine, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, People's Republic of China; 3 School of Clinical Medicine, Guangxi University of Chinese Medicine, Nanning, People's Republic of China &astThese authors contributed equally to this work Correspondence: Zhenhan Deng Department of Sports Medicine, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, 3002 Sungang West Road, Shenzhen City, 518035, People's Republic of China , Tel +86 13928440786 , Fax +86 755-83366388 , Email ; Liangjun Li Department of Orthopaedics, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, 161 Shaoshan South Road, Changsha City, 410018, People's Republic of China , Tel +86 13875822004 , Fax +86 731-85668156 , Email Osteoarthritis (OA) is an aging-related joint disease, pathologically featured with degenerated articular cartilage and deformation of subchondral bone. OA has become the fourth major cause of disability in the world, imposing a huge economic burden. At present, the pathogenesis and pathophysiology of OA are still unclear. Complex regulating networks containing different biochemical signaling pathways are involved in OA pathogenesis and progression. The p38MAPK signaling pathway is a member of the MAPK signaling pathway family, which participates in the induction of cellular senescence, the differentiation of chondrocytes, the synthesis of matrix metalloproteinase (MMPs) and the production of pro-inflammatory factors. In recent years, studies on the regulating role of p38MAPK signaling pathway and the application of its inhibitors have attracted growing attention, with an increasing number of in vivo and in vitro studies. One interesting finding is that the inhibition of p38MAPK could suppress chondrocyte inflammation and ameliorate OA, indicating its therapeutic role in OA treatment. Based on this, we reviewed the mechanisms of p38MAPK signaling pathway in the pathogenesis of OA, hoping to provide new ideas for future research and OA treatment. Keywords: osteoarthritis, p38MAPK signaling pathway, aging, inflammation Osteoarthritis (OA) is a leading cause of joint pain and disability, bringing huge socioeconomic costs in the global context. 1,2 There are approximately 300 million individuals worldwide who are suffering from OA. 3 OA is characterized by progressive degeneration of the articular cartilage (AC) and ligaments, as well as chronic synovitis and abnormal bone remodeling. Knee and hip joints are the most commonly affected synovial joints. 4 With the progression of OA, patients will suffer from increasingly severe pain, limited autonomic activity, and even disability. Recent studies indicate that the progression of OA is affected by multiple factors, such as aging, gender, genetics, obesity, etc. 5 However, most of the current therapies for OA, including the oral administration of non-steroidal anti-inflammatory drugs (NSAIDs) and glucosamine, are limited to symptom relief and pain management. Disease-modifying drugs which can reverse the progression of OA are still not available. 6 Orthopedic surgeries, typically total joint replacement surgeries, remain the last choice for OA treatment. 7 Although orthopedic surgeries are able to improve the quality of life to some extent, potential complications such as pain, opioid abuse, infection, and poorer joint function must be taken into consideration when opting for surgical intervention. 8,9 Thus, finding new therapeutic targets for the development of disease-modifying treatments is of great importance. The mitogen-activated protein kinase (MAPK) is a kind of serine/threonine protein kinase widely existing in eukaryotic cells. It can be activated by multiple internal and external stimulators, such as extracellular signals, physical stimulation, bacteria, tumor growth factor (TGF) and inflammatory cytokines like interleukin (IL)-1 and IL-6. After being activated, MAPK transfers the extracellular signal to the nucleus and regulates the activity of transcription factors, which will eventually alter the expression of related genes and induce cell reaction. 10 Existing research suggests that the MAPK signaling pathway and OA progression are internally related. The dysregulation of the MAPK si -Abstract Truncated-

p38 MAPK signalling cascades and inflammatory disease

Function and inhibition of P38 MAP kinase signaling: Targeting multiple inflammation diseases

Functional Roles of p38 Mitogen-Activated Protein Kinase in Macrophage-Mediated Inflammatory Responses

The journey of p38 MAP kinase inhibitors: From bench to bedside in treating inflammatory diseases

p38 MAPK Activity Is Required to Prevent Hyperactivation of NLRP3 Inflammasome

Recent Advance on P38 Mitogen-Activated Protein Kinases Inhibitors

Activation of the P38/CREB/MMP 13 Axis is Associated with Osteoarthritis

p38 MAPK inhibits autophagy and promotes microglial inflammatory responses by phosphorylating ULK1

Regulation of Mitogen-Activated Protein Kinase Activated Protein Kinase-2 on Expression of Important Inflammatory Mediators in Acute Lung Injury

THE MITOGEN-ACTIVATED PROTEIN KINASE p38 IS NECESSARY FOR INTERLEUKIN-1β-INDUCED MONOCYTE CHEMOATTRACTANT PROTEIN 1 EXPRESSION BY HUMAN MESANGIAL CELLS

The p38MAPK-MK2 Signaling Axis as a Critical Link Between Inflammation and Synaptic Transmission

P38 Mapk Contributes to Cd54 Expression and the Enhancement of Phagocytic Activity During Macrophage Development

P38mapk Inhibitors and Protection of Acute Lung Injury

Role of p38 MAPK in ICAM-1 expression of vascular endothelial cells induced by lipopolysaccharide.

Inhibition of Inflammation by a P38 MAP Kinase Targeted Cell Permeable Peptide

p38 in macrophages aggravates arterial endothelium injury by releasing IL-6 through phosphorylating megakaryocytic leukemia 1

Feedback Control of MKP-1 Expression by P38

Inhibition of the p38 pathway upregulates macrophage JNK and ERK activities, and the ERK, JNK, and p38 MAP kinase pathways are reprogrammed during differentiation of the murine myeloid M1 cell line

Role of p38 Mitogen-Activated Protein Kinase in Asthma and COPD: Pathogenic Aspects and Potential Targeted Therapies

p38α in macrophages aggravates arterial endothelium injury by releasing IL-6 through phosphorylating megakaryocytic leukemia 1

p38MAPK Signaling Pathway in Osteoarthritis: Pathological and Therapeutic Aspects